SGLT



10 Item(s)

per page

Set Descending Direction
Catalog No. Product Name Application Product Information
A10285 SALE

Dapagliflozin (BMS512148)

SGLT2 inhibitor
Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney.
A13476

Luseogliflozin

SGLT2 Inhibitor
Luseogliflozin is an orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor developed by Taisho Pharmaceutical for the treatment of patients with type 2 diabetes mellitus (T2DM).
A13556 SALE

Ipragliflozin

SGLT2 inhibitor
Ipragliflozin is a highly potent and selective SGLT2 inhibitor with IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6.
A13971

Remogliflozin

SGLT2 inhibitor
Remogliflozin inhibits the sodium-glucose transport (SGLT2) proteins, which are responsible for glucose reabsorption in the kidney.
A12690

Tofogliflozin

SGLT2 inhibitor
Tofogliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney.
A12680 SALE

LX-4211

SGLT Inhibitor‎
LX4211 is a Dual SGLT1/SGLT2 Inhibitor
A12440 SALE

Empagliflozin

-
Empagliflozin is a potent, selective sodium glucose co-transporter-2 inhibitor that is in development for the treatment of type 2 diabetes.
A10155

EGT1442

SGLT2 inhibitor
EGT1442 is a potent and selective SGLT2 inhibitor.
A11100 SALE

Canagliflozin

SGLT2 Inhibitor
Canagliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2).
A15463 SALE

T-1095

Na+-glucose transporter inhibitor
T-1095 is a potent and selective inhibitor of Na+-glucose cotransporters (SGLTs).

10 Item(s)

per page

Set Descending Direction